ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

RSLS 11.12.2024

Full Press ReleaseSEC FilingsOur RSLS Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
  • 11.14.2024 - RSLS Third Quarter 2024 Earnings Call
  • 11.14.2024 - ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update

Recent Filings

  • 01.21.2025 - S-1 General form for registration of securities under the Securities Act of 1933
  • 01.21.2025 - 8-K Current report
  • 01.15.2025 - S-4/A Registration of securities, business combinations
PDF Version
FLEX Technology Designed to Improve the Patient Experience

IRVINE, Calif.,Nov. 12, 2024(GLOBE NEWSWIRE) --ReShape Lifesciences®(Nasdaq: RSLS),the premier physician-led weight loss and metabolic health solutions company, today announced thatHealth Canadahas updated the Medical Device License granting approval for the company’s next generation, enhanced Lap-Band®2.0 FLEX and Tubing Kit.

“Approval byHealth Canadafor the Lap-Band®2.0 FLEX is yet another significant milestone for ReShape and an important growth catalyst for the company’s Lap-Band®franchise,” statedPaul F. Hickey, President and Chief Executive Officer ofReShape Lifesciences. “As a reminder, the enhanced Lap-Band®2.0 FLEX was designed with physician feedback with the goal of improving the patient experience. Like the current Lap-Band, Lap-Band®2.0 FLEX can be adjusted postoperatively to increase or decrease the band opening, thus optimizing eating habits and comfort. Additionally, Lap-Band®2.0 FLEX has a new feature called Flex technology, which acts as a relief valve, enabling larger pieces of food to pass through the narrowed passage more easily. Specifically, the band momentarily relaxes before returning to its resting diameter, while minimizing discomfort caused by swallowing large food pieces. Recently, we have successfully completed the limited market release of the Lap-Band®2.0 FLEX in theU.S., and initial surgeon feedback has been overwhelmingly positive, we are analyzing data and metrics that will be used to support ourU.S.commercial launch. Additionally, we now look forward to launching the product inCanadain the near future.”

AboutReShape Lifesciences®ReShape Lifesciences®is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band®System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim NeuromodulationTM (DBSNTM) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon®balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visitwww.reshapelifesciences.com.

Forward-Looking Safe Harbor StatementThis press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about the company’s expected commercial launch of the Lap-Band®2.0 in theU.S.andCanada. These and additional risks and uncertainties are described more fully in the company's filings with theSecurities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

CONTACTSReShape Lifesciences Investor Contact:Paul F. HickeyPresident and Chief Executive Officer949-276-7223ir@ReShapeLifesci.com

Investor Relations Contact:Rx Communications GroupMichael Miller(917)-633-6086mmiller@rxir.com

Primary Logo

Source: ReShape Lifesciences Inc

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com